HC Wainwright Raises Biora Therapeutics (NASDAQ:BIOR) Price Target to $23.00

Biora Therapeutics (NASDAQ:BIOR) had its price target lifted by HC Wainwright from $15.00 to $23.00 in a research note issued to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

Biora Therapeutics Stock Up 0.6 %

Shares of NASDAQ BIOR opened at $1.63 on Monday. The firm has a market cap of $7.37 million, a price-to-earnings ratio of -0.12 and a beta of 1.27. Biora Therapeutics has a 52-week low of $1.43 and a 52-week high of $19.90. The business’s 50 day moving average is $4.44 and its two-hundred day moving average is $5.93.

About Biora Therapeutics

Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.